Breaking News Instant updates and real-time market news.

AMD

AMD

$20.31

-0.44 (-2.12%)

13:53
01/09/19
01/09
13:53
01/09/19
13:53

AMD CEO says seeing 'a little slowdown' in China, as others have noted

AMD President and CEO Dr. Lisa Su is being interviewed from the CES meeting on CNBC.

AMD AMD
$20.31

-0.44 (-2.12%)

12/20/18
BOFA
12/20/18
NO CHANGE
Target $27
BOFA
Buy
BofA/Merrill sees prolonged weakness in GPUs, lowers AMD price target to $27
BofA Merrill Lynch analyst Vivek Arya said his recent checks suggests there will be prolonged weakness in GPUs over the next few quarters and he trimmed his Q4 and 1H19 sales and EPS estimates for AMD in response. He expects a recovery starting in Q3 in graphics and more backend weighted growth from AMD's next-gen EPYC server chip, "Rome," Arya tells investors. The analyst, who lowered his 2018 EPS estimate by 2c to 44c, which is below the Street at 46c, and lowered his 2019 EPS by 8c to be in-line with consensus at 62c, cut his price target on AMD shares to $27 from $30. Arya keeps a Buy rating on AMD.
12/21/18
DAIW
12/21/18
INITIATION
Target $26
DAIW
Buy
AMD initiated with a Buy at Daiwa
Daiwa initiated AMD with a Buy and $26 price target.
12/27/18
RBCM
12/27/18
NO CHANGE
Target $200
RBCM
Outperform
Nvidia, AMD estimates lowered at RBC Capital on more cautious gaming view
RBC Capital analyst Mitch Steves lowered his price target on Nvidia (NVDA) to $200 from $230 and also lowered his FY19 revenue forecast on Advanced Micro Devices (AMD) to $7.29B from $7.41B. The analyst says the revisions reflect his observation of a reduction in average selling prices for GPUs of both companies in the secondary market, particularly for Nvidia's GTX 1070 gaming chip. Steves warns that the company may not be able to discern whether the lower prices come as a result of reduced demand in gaming or cryptocurrency related activity, but states that his expectations for Gaming sector are "conservative". The analyst also expects both Nvidia and AMD stocks to remain range bound until the air-pocket in gaming has passed over the near term. Longer term, Steves keeps his Outperform rating on Nvidia amid the sales mix shift toward Data Center revenues, which is seeing traction with the expected annualized growth. For AMD, the analyst also maintains an Outperform rating stating that its long-term investment story remains unchanged. In Q1, Steves sees AMD catalysts in the form a new server product with competitive performance and price relative to the current Intel (INTC) offerings.
01/04/19
01/04/19
UPGRADE
Target $60

Buy
BofA/Merrill prefers cloud and 5G exposure in semis, upgrades Intel to Buy
As previously reported, BofA Merrill Lynch analyst Vivek Arya upgraded Intel (INTC) to Buy from Neutral, stating that the stock provides attractive exposure to growth trends in cloud computing, AI, advanced autos and 5G. He forecasts total semiconductor industry sales to decelerate to down 3% year-over-year in 2019 and still expects enterprise, data center and parts of networking infrastructure to perform better than cyclical sectors such as industrial, automotive and smartphones, Arya tells investors. Risks, such as AMD (AMD) share loss, 7nm product delays, and tougher PC/data center comps, do exist, but now appear to be reflected in Intel shares, the analyst added. He raised his price target on Intel shares to $60 from $52.

TODAY'S FREE FLY STORIES

ATNI

ATN International

$59.50

-15.62 (-20.79%)

07:44
02/22/19
02/22
07:44
02/22/19
07:44
Upgrade
ATN International rating change  »

ATN International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 22

    Mar

  • 28

    Mar

AAOI

Applied Optoelectronics

$14.62

(0.00%)

07:42
02/22/19
02/22
07:42
02/22/19
07:42
Downgrade
Applied Optoelectronics rating change  »

Applied Optoelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

UCTT

Ultra Clean

$12.59

-0.26 (-2.02%)

07:42
02/22/19
02/22
07:42
02/22/19
07:42
Downgrade
Ultra Clean rating change  »

Ultra Clean downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBM

Cambrex

$40.21

1.935 (5.06%)

, GILD

Gilead

$65.55

-1.43 (-2.14%)

07:41
02/22/19
02/22
07:41
02/22/19
07:41
Downgrade
Cambrex, Gilead rating change  »

Jefferies downgrades…

CBM

Cambrex

$40.21

1.935 (5.06%)

GILD

Gilead

$65.55

-1.43 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CHRA

Charah Solutions

$6.80

0.005 (0.07%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Downgrade
Charah Solutions rating change  »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONE

CyrusOne

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Downgrade
CyrusOne rating change  »

Jefferies downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

ARAY

Accuray

$5.26

0.09 (1.74%)

07:38
02/22/19
02/22
07:38
02/22/19
07:38
Hot Stocks
Accuray reports results from SBRT trial »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$64.31

-0.35 (-0.54%)

07:36
02/22/19
02/22
07:36
02/22/19
07:36
Upgrade
Citi rating change  »

Jefferies sees positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

BCLI

BrainStorm

$3.88

0.01 (0.26%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Hot Stocks
BrainStorm announces first U.S.clinical site for Phase 2 MS study »

BrainStorm announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Earnings
Breaking Earnings news story on W.P. Carey »

W.P. Carey sees FY19 AFFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

KEYS

Keysight Technologies

$81.74

0.67 (0.83%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Recommendations
Keysight Technologies analyst commentary  »

Keysight Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

, KR

Kroger

$28.55

-0.2 (-0.70%)

07:35
02/22/19
02/22
07:35
02/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

WFT

Weatherford

$0.78

-0.0436 (-5.32%)

KR

Kroger

$28.55

-0.2 (-0.70%)

I

Intelsat

$24.59

0.5 (2.08%)

BSX

Boston Scientific

$40.12

-0.01 (-0.02%)

OAS

Oasis Petroleum

$6.07

-0.28 (-4.41%)

MNST

Monster Beverage

$58.87

0.16 (0.27%)

LKQ

LKQ Corp.

$27.33

0.36 (1.33%)

DK

Delek US

$36.18

-0.8953 (-2.41%)

AGI

Alamos Gold

$4.82

-0.055 (-1.13%)

APEI

American Public Education

$32.93

0.88 (2.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 28

    Mar

  • 18

    May

  • 22

    May

  • 28

    May

07:35
02/22/19
02/22
07:35
02/22/19
07:35
General news
Treasury Market Outlook: yields are lower in the U.S. and Europe »

Treasury Market Outlook:…

WPC

W.P. Carey

$74.39

0.25 (0.34%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
W.P. Carey reports Q4 AFFO $1.33, consensus $1.33 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BXG

Bluegreen Vacations

$13.92

-0.12 (-0.85%)

07:34
02/22/19
02/22
07:34
02/22/19
07:34
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TEF

Telefonica

$8.85

0.12 (1.37%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
EU says Telefonica breached commitment in E-Plus acquisition »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CONE

CyrusOne

$52.44

-4.75 (-8.31%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Recommendations
CyrusOne analyst commentary  »

CyrusOne price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Mar

  • 18

    Jun

BIIB

Biogen

$320.99

-14.02 (-4.18%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:33
02/22/19
02/22
07:33
02/22/19
07:33
Hot Stocks
Insmed sees FY19 ARIKAYCE revenues $80M-$90M »

Insmed expects cash-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

OPNT

Opiant Pharmaceuticals

$14.65

-0.25 (-1.68%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Recommendations
Opiant Pharmaceuticals analyst commentary  »

Opiant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$418.66

-3.9 (-0.92%)

07:32
02/22/19
02/22
07:32
02/22/19
07:32
Downgrade
Regeneron rating change  »

Regeneron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

  • 11

    Mar

  • 28

    Apr

  • 13

    May

INSM

Insmed

$25.57

-0.42 (-1.62%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Earnings
Insmed reports Q4 EPS ($1.19), consensus ($1.06) »

Reports Q4 revenue $9.8M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SHW

Sherwin-Williams

$438.49

0.56 (0.13%)

07:31
02/22/19
02/22
07:31
02/22/19
07:31
Recommendations
Sherwin-Williams analyst commentary  »

Sherwin-Williams price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$47.88

0.35 (0.74%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Initiation
Zogenix initiated  »

Zogenix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$10.03

-0.07 (-0.69%)

, JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

07:30
02/22/19
02/22
07:30
02/22/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$10.03

-0.07 (-0.69%)

JNJ

Johnson & Johnson

$135.40

-0.91 (-0.67%)

M

Macy's

$24.44

-0.58 (-2.32%)

CZR

Caesars

$9.42

-0.21 (-2.18%)

KEM

Kemet

$18.87

-0.56 (-2.88%)

COUP

Coupa Software

$92.20

-1.55 (-1.65%)

SM

SM Energy

$17.01

-2.69 (-13.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 03

    Mar

  • 06

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.